No new randomized trial, no FDA label update, and no payer guidance crossed the wire this week on GLP-1 receptor agonists for alcohol use disorder. The Klausen Lancet 108-patient RCT — adults with AUD and obesity, 26 weeks, CBT co-intervention — remains the bounding artifact. The paper's May 19 feature on the trial boundary, not bar story frame holds for another seven days.

Mayo Clinic Press's March 18 conversation with dietitian Tara Schmidt — the most substantive mainstream treatment of where GLP-1 use is heading — confirmed that as of recording the FDA approvals are still diabetes and obesity, with cardiovascular risk reduction added. [1] The interview noted research under way on chronic kidney disease, metabolic-associated steatohepatitis, and substance-use applications, but framed each as a study, not a prescribing reality.

Schmidt was explicit that GLP-1 effects on dopamine and pleasure centers may explain the addiction-research signal, while flagging mixed 2024 and 2025 evidence on depression and suicidal ideation in users with prior mental-health risk. [1] The FDA and the European Medicines Agency have so far judged the drugs safe on that endpoint. The phrase that surfaced was "life feeling a little bit beige" — a side-effect category, not an off-label promise.

The X discourse this week kept GLP-1 alcohol claims in the lifestyle-press register, as if the trial were a culture trend. It is not. It is a study with a population, a duration, a comparator, a CBT layer, and a primary endpoint. For a patient with AUD considering whether a GLP-1 belongs in the treatment plan, the conversation is with a clinician, not a feed.

The trial boundary held. So did the wait.

-- NORA WHITFIELD, Chicago